Advances in Therapy · 2017 · 33 citations · 35 references
MedicineOncologyClinical Decision SupportEndocrine OncologyGastrointestinal OncologyCancer StagingCancer Treatment PlanningEndocrine Tumor PrognosisMultidisciplinary Cancer CareNeuroendocrine Tumor TherapyShared Decision-makingDecision CriterionGastroenteropancreatic Neuroendocrine Tumor DiagnosisReflection ProcessesShared Decision-making PolicyShared Prognostic Decision-makingSomatostatin AnaloguesTreatment Decision-making SupportWell-differentiated Neuroendocrine Tumors
INTRODUCTION: Well- or moderately differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are often slow-growing, and some patients with unresectable, asymptomatic, non-functioning tumors may face the choice between watchful waiting (WW), or somatostatin analogues (SSA) to delay progression. We developed a comprehensive multi-criteria decision analysis (MCDA) framework to help patients and physicians clarify their values and preferences, consider each decision criterion, and support communication and shared decision-making. METHODS: The framework was adapted from a generic MCDA framework (EVIDEM) with patient and clinician input. During a workshop, patients and clinicians expressed their individual values and preferences (criteria weights) and, on the basis of two scenarios (treatment vs WW; SSA-1 [lanreotide] vs SSA-2 [octreotide]) with evidence from a literature review, expressed how consideration of each criterion would impact their decision in favor of either option (score), and shared their knowledge and insights verbally and in writing. RESULTS: The framework included benefit-risk criteria and modulating factors, such as disease severity, quality of evidence, costs, and constraints. Overall and progression-free survival being most important, criteria weights ranged widely, highlighting variations in individual values and the need to share them. Scoring and considering each criterion prompted a rich exchange of perspectives and uncovered individual assumptions and interpretations. At the group level, type of benefit, disease severity, effectiveness, and quality of evidence favored treatment; cost aspects favored WW (scenario 1). For scenario 2, most criteria did not favor either option. CONCLUSIONS: Patients and clinicians consider many aspects in decision-making. The MCDA framework provided a common interpretive frame to structure this complexity, support individual reflection, and share perspectives. FUNDING: Ipsen Pharma.
35
The National Comprehensive Cancer Network
William T. McGivney · Cancer · 1998 · 16.9K citations
Anja Rinke, Hans‐Helge Müller, Carmen Schade‐Brittinger et al. · Journal of Clinical Oncology · 2009 · 2.5K citations
Medicine, Oncology, Pharmacotherapy +17
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Martyn Caplin, Marianne Pavel, Jarosław B. Ćwikła et al. · New England Journal of Medicine · 2014 · 1.9K citations · Full text
Medicine, Endocrinology, Oncology +17
Praveen Thokala, Nancy Devlin, Kevin Marsh et al. · Value in Health · 2016 · 721 citations · Full text